key: cord-0984851-967rxomd authors: Hadadi, Azar; Mortezazadeh, Masoud; Kolahdouzan, Kasra; Alavian, Golbarg title: Does recombinant human erythropoietin administration in critically ill COVID‐19 patients have miraculous therapeutic effects? date: 2020-04-19 journal: J Med Virol DOI: 10.1002/jmv.25839 sha: 9c5bc01c13737f458cc669edb775c61d6ced8ea5 doc_id: 984851 cord_uid: 967rxomd An 80‐year‐old man with multiple comorbidities presented to the emergency department with tachypnea, tachycardia, fever, and critically low O(2) saturation and definitive chest computerized tomography scan findings in favor of COVID‐19 and positive PCR results in 48 hours. He received antiviral treatment plus recombinant human erythropoietin (rhEPO) due to his severe anemia. After 7 days of treatment, he was discharged with miraculous improvement in his symptoms and hemoglobin level. We concluded that rhEPO could attenuate respiratory distress syndrome and confront the severe acute respiratory syndrome coronavirus 2 virus through multiple mechanisms including cytokine modulation, antiapoptotic effects, leukocyte release from bone marrow, and iron redistribution away from the intracellular virus. By the time of this writing COVID-19 pandemic has caused over 462 000 confirmed infected cases and 20 000 deaths in more than 200 countries and territories all over the world. 1 Due to its capability of rapid contamination, this virus is very infectious and has caused significant mortality especially in the elderly and populations with comorbidities. The risk factors for developing acute respiratory distress syndrome (ARDS) and subsequent death in COVID-19, have been reported to be age ≥65, neutrophilia, and development of organ failure and coagulation dysfunction. 2 Many interventions have been used to prevent the virus from progressing further in the host but in vulnerable patients, it finally progresses towards ARDS and cardiopulmonary arrest. In the present study, we report a patient with COVID-19 who after treating with recombinant human erythropoietin (rhEPO) due to his severe anemia, exhibited primarily unexplainable rapid symptoms relief and viral regression. An 80-year-old man with a past medical history of Alzheimer's disease and depression was brought to the emergency department because of a 20-day history of lightheadedness, fainting, progressive weakness, confusion, loss of appetite, fever, cough, and dyspnea. The initial physical examination showed a body temperature of 38.9°C, blood pressure of 96/60 mm Hg, pulse rate of 120 beats/minute, respiratory rate of 32 breaths/minute, and oxygen saturation of 80% while the patient was breathing without supplemental oxygen. He also had generalized pallor, bilateral crackles especially in the right lung, no sign of bleeding in digital rectal examination. Other physical exam findings were unremarkable. One week before his admission, the patient's CBC findings were: WBC 6.2 K/μL, Hgb 7 g/dL, PLT count 140 000 cell/mm 3 , MCV 89 fL. Transfusion of one unit of packed red blood cell (RBC) and adequate hydration was prescribed for the patient. According to COVID-19 national committee treatment protocols, the following medications were started: Lab data results also showed improvements in lymphocyte count which increased from 333 to 933 cell/µL, and Hgb concentration raised from 5.2 to 6.7 g/dL after one unit of packed RBC transfusion and then up to 9 g/dL after rhEPO administration (Table 1 ). As mentioned above rhEPO was prescribed for an 80-year-old confirmed case of COVID-19 due to his initial severe anemia in addition to antivirals. Subsequently, a very fast response considering his age and past medical history both in anemia correction (from Hb:6.7 to Hb:9) and COVID-19 symptom relief was observed that could not be elabo- Note: On day 1, one unit of packed RBC was transfused. On days 1, 3, 5, and 7, 4000 IU rhEPO was administered subcutaneously. One week after discharge in follow-up, he did not have any of the initial symptoms and the oxygen saturation was 94% in the room air. Abbreviation: rhEPO, recombinant human erythropoietin. F I G U R E 2 Molecular pathways associated with EPO signaling within the cell. EPO, erythropoietin; EPO-R, erythropoietin receptor HADADI ET AL. World Health Organization Available from: www.who Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China Erythropoietin and nonhematopoietic Effects Erythropoietin in critical illness and trauma Protective effects of erythropoietin towards acute lung injuries in rats with sepsis and its related mechanisms Erythropoietin inhibits respiratory epithelial cell apoptosis in a model of acute lung injury Protective effect of erythropoietin against lipopolysaccharide induced inflammation and mitochondrial damage in liver Erythropoietin attenuates LPS-induced microvascular damage in a murine model of septic acute kidney injury Erythropoietin attenuates renal and pulmonary injury in polymicrobial induced-sepsis through EPO-R, VEGF and VEGF-R2 modulation Protective effect of erythropoietin against myocardial injury in rats with sepsis and its underlying mechanisms Bone marrow endothelial cells induce immature and mature B cell egress in response to erythropoietin Iron and infection Viral infection and iron metabolism Cancer-related anemia and recombinant human erythropoietin-an updated overview Advances in understanding sepsis Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis Erythropoetin as a novel agent with pleiotropic effects against acute lung injury Does recombinant human erythropoietin administration in critically ill COVID-19 patients have miraculous therapeutic effects